Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Unicycive Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
UNCY
Nasdaq
8731
https://unicycive.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®
- Jun 9th, 2023 1:00 pm
Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook
- May 17th, 2023 10:03 am
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
- May 16th, 2023 12:29 pm
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
- Apr 24th, 2023 11:00 am
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
- Mar 31st, 2023 11:00 am
Shareholders have faith in Unicycive Therapeutics (NASDAQ:UNCY) as stock climbs 36% in past week, taking one-year gain to 99%
- Mar 8th, 2023 11:04 am
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
- Mar 7th, 2023 2:00 pm
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
- Mar 6th, 2023 12:00 pm
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
- Mar 3rd, 2023 2:15 pm
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
- Feb 27th, 2023 12:00 pm
Unicycive: The Company Developing Key Kidney Therapies
- Feb 17th, 2023 3:35 pm
Unicycive: This Biotech Company Receives Promising Results From New Trial
- Feb 6th, 2023 2:59 pm
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
- Feb 2nd, 2023 1:30 pm
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
- Jan 23rd, 2023 12:00 pm
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
- Jan 5th, 2023 12:00 pm
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
- Dec 29th, 2022 4:31 pm
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
- Dec 28th, 2022 2:21 pm
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
- Dec 28th, 2022 1:30 pm
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
- Dec 22nd, 2022 12:00 pm
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
- Dec 9th, 2022 1:00 pm
Scroll